LYNPARZA

Active substance

olaparib

Holder

AstraZeneca

Status

Closed

Indication

Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Public documents

Approbation

Information for the patient

Informed consent

Last update

12/05/2020

Last updated on 13/02/2024